Published Data Confirms First 3D Ultrasound for Breast Cancer Treatment Planning Helps Radiation Oncologists Better Define Treatment Region
International Journal of Radiation Oncology*Biology*Physics Study Finds that Resonant Medical’s Clarity Breast System Provides Enhanced Image Information for Planning Partial Breast Irradiation Treatment
The study, “3D Ultrasound Can Contribute to Planning CT to Define the Target for Partial Breast Radiotherapy,” conducted at the Radiation Therapy Program, British Columbia Cancer Agency, Vancouver Island Centre and the
“Precision in planning and the increased certainty that radiation is being delivered to the exact area where it is needed have never been more critical, with the percentage of patients opting for breast conservation therapy and PBI on the rise,” said
The Clarity Breast System marks the first application of 3D ultrasound technology to Image-Guided Radiation Therapy (IGRT) in breast cancer. The Clarity system was cleared by the U.S. Food and Drug Administration in 2004 for guidance in the treatment of prostate and breast cancers.
In addition to its application with treatment planning, the Clarity System is also used to image the lumpectomy cavity daily with each radiation treatment, to get an actual visual image and location of the tumor cavity on a regular basis. While the breast cancer radiation oncology community is aware that the location of the lumpectomy cavity target can change throughout the course of treatment, this issue is still largely unaccounted for in current treatment protocols. Clinical consequences can include delivery of radiation to healthy tissue, application of radiation too close to the chest wall or skin and, in some cases, under-treatment of certain areas. Clarity provides the first method of daily lumpectomy cavity monitoring that is based on visualization of the actual anatomy–rather than an estimation of the location of the cavity. This precision in planning and treatment could enable physicians to reduce the field of radiation they need to deliver, which is always preferable if clinically justified.
Several studies detailing the benefits of the use of Clarity during breast cancer treatment have also been presented in recent months. For example:
- At the 2008 Annual Meeting of the American Society for Therapeutic Radiation Oncology (ASTRO), data from a study conducted at
McGill Universityand the University of Vermontwas presented investigating the use of the Clarity system to track tumor cavity movement prior to daily treatments. The study compared the use of 3D ultrasound to CT, and found that these techniques were statistically equivalent. Researchers concluded that because ultrasound is non-ionizing and non-invasive, it is preferable to daily CT for tumor cavity monitoring.
- Additionally, at the 2008 meeting of the Radiological Society of
North America(RSNA), data collected at Beth Israel Medical Center in New Yorkon the use of Clarity when delivering electron boost therapy was examined. Although electron boost treatments have been delivered for quite some time, there has been no way to ensure that the electron dose is treating the correct area. This study found that in 45 percent of treatments, part of the tumor cavity would have been outside of the dose region and would have been missed without ultrasound guidance.
“The Clarity System has been used in the treatment of thousands of prostate cancer patients, and we are encouraged by the results and feedback we have seen and heard from radiation oncologists regarding its application with breast cancer,” said
About Resonant Medical
Resonant Medical (
Contacts: Wendy Ryan/Jasmine Fielding Schwartz Communications (781) 684-0770 Resonant@schwartz-pr.com
SOURCE Resonant Medical